HK1042436A1 - Method for preventing or delaying catheter-based revascularization. - Google Patents

Method for preventing or delaying catheter-based revascularization.

Info

Publication number
HK1042436A1
HK1042436A1 HK02104071A HK02104071A HK1042436A1 HK 1042436 A1 HK1042436 A1 HK 1042436A1 HK 02104071 A HK02104071 A HK 02104071A HK 02104071 A HK02104071 A HK 02104071A HK 1042436 A1 HK1042436 A1 HK 1042436A1
Authority
HK
Hong Kong
Prior art keywords
preventing
based revascularization
delaying
catheter
delaying catheter
Prior art date
Application number
HK02104071A
Other languages
English (en)
Inventor
Donald Michael Black
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1042436(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1042436A1 publication Critical patent/HK1042436A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Surgical Instruments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
HK02104071A 1998-09-30 2002-05-31 Method for preventing or delaying catheter-based revascularization. HK1042436A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30
PCT/US1999/015385 WO2000018395A1 (en) 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number Publication Date
HK1042436A1 true HK1042436A1 (en) 2002-08-16

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104071A HK1042436A1 (en) 1998-09-30 2002-05-31 Method for preventing or delaying catheter-based revascularization.

Country Status (35)

Country Link
US (1) US20080119561A1 (sh)
EP (1) EP1117392B1 (sh)
JP (1) JP2002525321A (sh)
KR (1) KR20010079955A (sh)
CN (1) CN1197565C (sh)
AP (1) AP1708A (sh)
AT (1) ATE260100T1 (sh)
AU (1) AU768474B2 (sh)
BG (1) BG105471A (sh)
BR (1) BR9914098A (sh)
CA (1) CA2343299C (sh)
CZ (1) CZ20011035A3 (sh)
DE (1) DE69915084T2 (sh)
DK (1) DK1117392T3 (sh)
EA (1) EA007427B1 (sh)
EE (1) EE200100199A (sh)
ES (1) ES2214872T3 (sh)
HK (1) HK1042436A1 (sh)
HR (1) HRP20010236A2 (sh)
HU (1) HUP0103648A3 (sh)
ID (1) ID30255A (sh)
IL (2) IL141953A0 (sh)
IS (1) IS5889A (sh)
NO (1) NO20011615L (sh)
NZ (1) NZ510500A (sh)
OA (1) OA11787A (sh)
PL (1) PL346980A1 (sh)
PT (1) PT1117392E (sh)
SI (1) SI1117392T1 (sh)
SK (1) SK4122001A3 (sh)
TR (1) TR200100901T2 (sh)
UA (1) UA73292C2 (sh)
WO (1) WO2000018395A1 (sh)
YU (1) YU23901A (sh)
ZA (1) ZA200102230B (sh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
EP1303266A1 (en) * 2000-07-14 2003-04-23 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
US5957916A (en) * 1994-05-25 1999-09-28 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1997016184A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
WO1998001100A2 (en) * 1996-07-09 1998-01-15 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
SI1117392T1 (en) 2004-06-30
NZ510500A (en) 2003-10-31
SK4122001A3 (en) 2002-06-04
ID30255A (id) 2001-11-15
CZ20011035A3 (cs) 2001-10-17
IL141953A (en) 2006-07-05
NO20011615D0 (no) 2001-03-29
ZA200102230B (en) 2002-06-18
CN1197565C (zh) 2005-04-20
PL346980A1 (en) 2002-03-11
EA007427B1 (ru) 2006-10-27
EA200100370A1 (ru) 2001-10-22
DE69915084T2 (de) 2004-07-22
DK1117392T3 (da) 2004-06-14
CA2343299C (en) 2008-04-01
HRP20010236A2 (en) 2002-04-30
EP1117392B1 (en) 2004-02-25
IS5889A (is) 2001-03-14
AP2001002112A0 (en) 2001-06-30
ES2214872T3 (es) 2004-09-16
OA11787A (en) 2005-07-26
UA73292C2 (en) 2005-07-15
WO2000018395A1 (en) 2000-04-06
JP2002525321A (ja) 2002-08-13
AU768474B2 (en) 2003-12-11
IL141953A0 (en) 2002-03-10
YU23901A (sh) 2003-07-07
TR200100901T2 (tr) 2001-08-21
HUP0103648A3 (en) 2003-10-28
EP1117392A1 (en) 2001-07-25
ATE260100T1 (de) 2004-03-15
BG105471A (en) 2001-12-31
US20080119561A1 (en) 2008-05-22
KR20010079955A (ko) 2001-08-22
CA2343299A1 (en) 2000-04-06
HUP0103648A2 (hu) 2003-08-28
PT1117392E (pt) 2004-07-30
AU4975099A (en) 2000-04-17
AP1708A (en) 2007-01-10
CN1342072A (zh) 2002-03-27
NO20011615L (no) 2001-04-24
BR9914098A (pt) 2001-07-31
EE200100199A (et) 2002-06-17
DE69915084D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
ZA200006011B (en) Object recognition method.
ZA200003030B (en) Beam.
ZA99254B (en) Benzosulfone derivatives.
ZA200007593B (en) Quinoline Derivatives.
ZA991975B (en) Enzyme inhibitors.
SG72964A1 (en) Etching method
ZA993230B (en) R.B. Jun method for surface mining.
ZA9811925B (en) Thiazole derivatives.
ID28874A (id) Inhibitor fosfodiesterase 4 turunan ftalazina.
AU6058899A (en) Penetration flux
HK1043119A1 (en) Chroman derivatives.
ZA200007405B (en) Angiogenesis inhibitors.
ZA993123B (en) Trisresorcinyltriazines.
AU4676499A (en) Treating solid, especially aluminum, surfaces
ZA993086B (en) Safe projectable target.
HK1042436A1 (en) Method for preventing or delaying catheter-based revascularization.
ZA99832B (en) Improved security arrangements.
GB9819418D0 (en) Amplification method
ZA994289B (en) Cyclooxygenase inhibitor.
ZA992106B (en) Statin-MMP inhibitor combinations.
ZA993536B (en) Autoclaves.
ZA200001575B (en) Waxes.
ZA992062B (en) Rotary Springkler.
AU4517199A (en) Demodulation method
ZA993449B (en) Drilling.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090708